InteRNA Technologies

InteRNA is a clinical-stage biotech company developing a pipeline of proprietary microRNA (miRNA) therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer.

InteRNA Technologies aspires to improve cancer therapy effectiveness through innovative, intelligent miRNA-based therapeutics.

InteRNA Technologies was founded in 2006 by Edwin Cuppen and Eugene Berezikov. The company is headquartered in Utrecht, Utrecht, Netherlands.

 

InteRNA uses its leading microRNA (miRNA) discovery and functional validation platform to develop a pipeline of proprietary preclinical miRNA drug candidates targeting key processes in cancer initiation and progression.

 

InteRNA directly targets tumor cells and the tumor microenvironment by specific modulation of multiple signaling pathway components across the PTEN tumor suppressor pathway and the oncogenic PI3K/Akt and Ras/MAPK pathways resulting in inhibition of proliferation and migration and induction of cell cycle arrest and apoptosis.

 

InteRNA is backed by AurorA Science, Waterman Ventures, Aglaia Oncology Funds, OostNL, INKEF Capital and others. The company closed of an extended Series B Round, totaling to €18.5M ($22.5M). This brings additional financing brings InteRNA's total funding to $34.7M to date.

 

 

  • Year founded: 2006
  • Funding Info: $34.7M over 5 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Utrecht
  • State: Utrecht
  • Country: Netherlands
Related businesses